It may therefore be possible that B cells in the tumor-microenvironment are coerced into developing a regulatory phenotype (TGFβ+ and IL-10+), and that tumor-derived antigens in general could induce B cell IL-10-expression (57). The gene discussed is TGFB1; the disease is neoplasm.